To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis

NCT ID: NCT03412682

Last Updated: 2020-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

274 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-02

Study Completion Date

2020-05-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colitis, Ulcerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Budesonide (6 mg)

Group Type EXPERIMENTAL

Budesonide (6 mg)

Intervention Type DRUG

Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Budesonide (9 mg)

Group Type EXPERIMENTAL

Budesonide (9 mg)

Intervention Type DRUG

Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Mesalazine (3,600 mg)

Group Type ACTIVE_COMPARATOR

Mesalazine (3,600 mg)

Intervention Type DRUG

Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budesonide (6 mg)

Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Intervention Type DRUG

Budesonide (9 mg)

Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Intervention Type DRUG

Mesalazine (3,600 mg)

Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FE 999315 FE 999315

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients, 16 to 75 years old, diagnosed with ulcerative colitis.
* Diagnosis of ulcerative colitis in active phase of mild to moderate entity.
* Female patients must fulfill at least one of the following criteria: Post-menopausal (women ≥45 years with no menstrual period for at least 12 months without an alternative medical cause), surgically sterile, using a medically approved contraception throughout the trial period or her male partner using medically approved contraception throughout the trial period.
* Male patients must agree to use medically approved contraception throughout the trial period.

Exclusion Criteria

* Patients with limited distal proctitis.
* Patients with infectious colitis.
* Patients with history of colectomy.
* Patients with severe diseases in other organs and systems.
* Evidence or history of toxic megacolon.
* Women who wish to become pregnant during the trial period
Minimum Eligible Age

16 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ferring Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Compliance

Role: STUDY_DIRECTOR

Ferring Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ferring Investigator Site JPN27

Nagoya, Aichi-ken, Japan

Site Status

Ferring Investigator Site JPN52

Toyoake-shi, Aichi-ken, Japan

Site Status

Ferring Investigator Site JPN47

Toyota-shi, Aichi-ken, Japan

Site Status

Ferring Investigator Site JPN69

Abiko-shi, Chiba, Japan

Site Status

Ferring Investigator Site JPN68

Kashiwa-shi, Chiba, Japan

Site Status

Ferring Investigator Site JPN53

Urayasu-shi, Chiba, Japan

Site Status

Ferring Investigator Site JPN08

Matsuyama, Ehime, Japan

Site Status

Ferring Investigator Site JPN50

Fukui-shi, Fukui, Japan

Site Status

Ferring Investigator Site JPN51

Chikushino-shi, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN31

Fukuoka, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN64

Fukuoka, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN28

Kitakyushu, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN19

Kitakyushu-shi, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN23

Kitakyushu-shi, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN35

Kitakyushu-shi, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN38

Kurume-shi, Fukuoka, Japan

Site Status

Ferring Investigator Site JPN36

Gifu, Gifu, Japan

Site Status

Ferring Investigator Site JPN17

Takasaki-shi, Gunma, Japan

Site Status

Ferring Investigator Site JPN46

Hatsukaichi, Hiroshima, Japan

Site Status

Ferring Investigator Site JPN11

Asahikawa-shi, Hokkaido, Japan

Site Status

Ferring Investigator Site JPN59

Hakodate-shi, Hokkaido, Japan

Site Status

Ferring Investigator Site JPN61

Sapporo, Hokkaido, Japan

Site Status

Ferring Investigator Site JPN14

Kobe, Hyōgo, Japan

Site Status

Ferring Investigator Site JPN13

Nishinomiya-shi, Hyōgo, Japan

Site Status

Ferring Investigator Site JPN40

Nishinomiya-shi, Hyōgo, Japan

Site Status

Ferring Investigator Site JPN43

Kasama-shi, Ibaraki, Japan

Site Status

Ferring Investigator Site JPN24

Koga-shi, Ibaraki, Japan

Site Status

Ferring Investigator Site JPN22

Tsuchiura-shi, Ibaraki, Japan

Site Status

Ferring Investigator Site JPN41

Takamatsu, Kagawa-ken, Japan

Site Status

Ferring Investigator Site JPN02

Kagoshima, Kagoshima-ken, Japan

Site Status

Ferring Investigator Site JPN29

Kagoshima, Kagoshima-ken, Japan

Site Status

Ferring Investigator site JPN05

Yokohama, Kanagawa, Japan

Site Status

Ferring Investigator Site JPN33

Yokohama, Kanagawa, Japan

Site Status

Ferring Investigator Site JPN67

Yokohama, Kanagawa, Japan

Site Status

Ferring Investigator Site JPN63

Nankoku-shi, Kochi, Japan

Site Status

Ferring Investigator Site JPN34

Kyoto, Kyoto, Japan

Site Status

Ferring Investigator Site JPN48

Tsu, Mie-ken, Japan

Site Status

Ferring Investigator Site JPN12

Yokkaichi-shi, Mie-ken, Japan

Site Status

Ferring Investigator site JPN04

Sendai, Miyagi, Japan

Site Status

Ferring Investigator Site JPN44

Nagasaki, Nagasaki, Japan

Site Status

Ferring Investigator Site JPN66

Nagasaki, Nagasaki, Japan

Site Status

Ferring Investigator Site JPN62

Kashihara-shi, Nara, Japan

Site Status

Ferring Investigator Site JPN55

Niigata, Niigata, Japan

Site Status

Ferring Investigator Site JPN37

Beppu-shi, Oita Prefecture, Japan

Site Status

Ferring Investigator Site JPN01

Ōita, Oita Prefecture, Japan

Site Status

Ferring Investigator Site JPN72

Ōita, Oita Prefecture, Japan

Site Status

Ferring Investigator Site JPN65

Okayama, Okayama-ken, Japan

Site Status

Ferring Investigator site JPN07

Fujiidera-shi, Osaka, Japan

Site Status

Ferring Investigator Site JPN10

Osaka, Osaka, Japan

Site Status

Ferring Investigator Site JPN26

Osaka, Osaka, Japan

Site Status

Ferring Investigator Site JPN30

Osaka, Osaka, Japan

Site Status

Ferring Investigator Site JPN60

Sakai-shi, Osaka, Japan

Site Status

Ferring Investigator Site JPN39

Suita-shi, Osaka, Japan

Site Status

Ferring Investigator Site JPN21

Takatsuki-shi, Osaka, Japan

Site Status

Ferring Investigator Site JPN57

Toyonaka-shi, Osaka, Japan

Site Status

Ferring Investigator Site JPN03

Saitama-shi, Saitama, Japan

Site Status

Ferring Investigator Site JPN09

Saitama-shi, Saitama, Japan

Site Status

Ferring Investigator Site JPN49

Sakura-shi, Saitama, Japan

Site Status

Ferring Investigator Site JPN42

Tokorozawa-shi, Saitama, Japan

Site Status

Ferring Investigator Site JPN56

Tokorozawa-shi, Saitama, Japan

Site Status

Ferring Investigator Site JPN70

Mibu, Tochigi, Japan

Site Status

Ferring Investigator Site JPN32

Fuchū-shi, Tokyo, Japan

Site Status

Ferring Investigator Site JPN20

Kodaira-shi, Tokyo, Japan

Site Status

Ferring Investigator Site JPN15

Machida-shi, Tokyo, Japan

Site Status

Ferring Investigator site JPN06

Meguro-ku, Tokyo, Japan

Site Status

Ferring Investigator Site JPN58

Minato-ku, Tokyo, Japan

Site Status

Ferring Investigator Site JPN71

Mitaka-shi, Tokyo, Japan

Site Status

Ferring Investigator Site JPN18

Oume-shi, Tokyo, Japan

Site Status

Ferring Investigator Site JPN54

Shinagawa-Ku, Tokyo, Japan

Site Status

Ferring Investigator Site JPN45

Shinjuku-Ku, Tokyo, Japan

Site Status

Ferring Investigator Site JPN16

Kofu, Yamanashi, Japan

Site Status

Ferring Investigator Site JPN25

Hiroshima-shi, Hiroshima, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

000234

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.